News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Myriad Genetics, Inc. (MYGN) Sues Ambry Genetics to Thwart Rival Cancer Test


7/10/2013 8:13:45 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Myriad Genetics Inc., a provider of tests for breast cancer risk, filed a lawsuit today to shut a competitor that set up shop last month after a mixed U.S. Supreme Court ruling on patents for genetic material. Ambry Genetics, a closely held company in Aliso Viejo, California, announced June 13 it would offer the breast cancer tests hours after a high court ruling that invalidated some of Myriad’s patent claims on genes linked to breast and ovarian cancer. Myriad said the Ambry tests infringe 10 other patents it owns or licenses on the testing process that weren’t part of that Supreme Court case. The other owners of the patents, comprising the University of Utah and University of Pennsylvania, Ontario’s Hospital for Sick Children and Endorecherche Inc., also joined in the suit against Ambry.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg
Read at Motley Fool
Read at Live Mint


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES